GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose.

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W.

Los Angeles, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Blueone Card Inc. (OTCQX:BCRD) is pleased to announce that its wholly owned subsidiary, Millennium EBS Inc., has entered into an agreement with DFCC Bank in Sri Lanka to implement Millennium's advanced ISO Transformer solution for SWIFT messaging.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Emergent Biosolutions (EBS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Emergent BioSolutions maintains a Buy rating, supported by recent Q3 earnings beat and CEO Joe Papa's turnaround progress. EBS reported Q3 revenues of $231.1M and net income of $51.2M, surpassing guidance, with improved capital allocation and reduced net debt. Narcan sales declined year-over-year due to pricing and volume pressures, but sequential growth and strong demand signal market stabilization.

Emergent Biosolutions (EBS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Emergent BioSolutions Inc. ( EBS ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Frank Vargo Joseph Papa - CEO, President & Director Richard Lindahl - Executive VP, CFO & Treasurer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $1.37 per share a year ago.

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior year Third Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38% Raising the Full Year 2025 Revenue and Profitability Guidance Strong Sequential Naloxone Revenue Growth, Primarily Driven by NARCAN® Nasal Spray, QoQ Through Q3 2025 GAITHERSBURG, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2025.

GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of a biological attack on U.S. soil is rising, yet almost half (45 percent) believe the U.S. is unprepared for a biological attack.